dapagliflozin/metformin hydrochloride

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Diabetes Mellitus, Type 2

Manufacturer:

AstraZeneca Canada Inc.

Call for patient/clinician input open:

December 1, 2015

Brand Name:

XigDuo

Project Line:

Reimbursement Review

Project Number:

SR0468-000

Call for patient/clinician input closed:

January 27, 2016

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Diabetes Mellitus, Type 2

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

July 20, 2016

Last Updated : March 22, 2024